title: New issues in systemic therapy for ovarian cancer.
abstract: Most patients with ovarian cancer require systemic therapy upfront and again on recurrence. Treatment advances over the past decade have been few, but bevacizumab prolongs disease remission, if not survival. Other targeted agents have not been effective, but emerging data for experimental agents suggest this outlook may change. In her presentation at the NCCN 18th Annual Conference, Dr. Deborah K. Armstrong reviewed findings supporting intraperitoneal chemotherapy, the use of bevacizumab, the use of neoadjuvant chemotherapy, and the potential of poly (ADP-ribose) polymerase (PARP) inhibitors and other newer agents.
authors.affiliation: Oncology, Gynecology and Obstetrics at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231- 1000, USA. armstde@jhmi.edu
authors.forename: Deborah K
authors.initials: DK
authors.lastname: Armstrong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D020360:Neoadjuvant Therapy; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab